BioMarin elects former Allergan CEO to board
pharmafile | January 5, 2016 | Appointment | Medical Communications, Research and Development, Sales and Marketing |
BioMarin Pharmaceutical has announced the election of former Allergan chief executive, David Pyott, to the company’s board of directors.
Pyott served as CEO of Allergan between 1998 and 2015, where he was recognised by the Harvard Business Review as one of “The 100 Best Performing CEOs in the World.” Under his leadership, Allergan transformed from a small eye care business with approximately $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014 and more than 10,000 employees. Pyott departed when the company merged with Actavis in 2014, about a year before Pfizer paid a record $160 billion for the combined Allergan.
“I am delighted to have David join BioMarin’s board of directors,” says Jean-Jacques Bienaimé, chairman and chief executive of BioMarin. “He is an accomplished executive who led Allergan to significant profitability through its global operations across 100 countries. As BioMarin prepares for regulatory filings with multiple new molecular entities in 2016, David’s expertise in organisational scaling will be instrumental as we pursue the next significant stage of growth for the company.”
Prior to Allergan, Pyott served as the head of the Novartis Nutrition Division and as a member of the company’s Executive Committee. Pyott is lead director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Directors of Alnylam Pharmaceuticals, and a member of the Supervisory Board of Royal Philips in the Netherlands. He is vice chairman of the Board of Trustees of Chapman University, a member of the Governing Board of the London Business School, president of the International Council of Ophthalmology Foundation, and a member of the Advisory Board of the Foundation of the American Academy of Ophthalmology.
